Loading patent…
AssigneeKorea Advanced Institute of Science and Technology
InventorsKwang Hyun Cho, Jung Eun Lee, Jeong Ryeol Gong
Estimating the term…
The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, comprising a DEAD-box helicase 54 (DDX54) inhibitor and a cancer immunotherapy agent, and to a combination therapy of cancer immunotherapy. The DDX54 inhibitor according to the present invention can enhance the efficacy of cancer immunotherapy when used in combination with a cancer immunotherapy agent, and the composition containing the DDX54 inhibitor and a cancer immunotherapy agent inhibits proliferation of cancer, which is a key characteristic thereof, and simultaneously inhibits a signal transduction pathway known as an immune evasion mechanism, and thus may be provided for the prevention or treatment of cancer.
A pharmaceutical composition for the prevention or treatment of cancer comprising a DEAD-box Helicase 54 (DDX54) inhibitor and a cancer immunotherapy agent.
A composition for enhancing the efficacy of cancer immunotherapy comprising a DEAD-box Helicase 54 (DDX54) inhibitor
A method for enhancing the efficacy of cancer immunotherapy, comprising co-administering a DEAD-box Helicase 54 (DDX54) inhibitor and a cancer immunotherapy agent to a subject.
A method for treating cancer comprising administering a DEAD-box Helicase 54 (DDX54) inhibitor and a cancer immunotherapy agent to a subject.
Dependencies are inferred from the claim text.